A groundbreaking study reveals a novel treatment for narcolepsy type 1, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. Researchers have discovered that oveporexton, an orexin receptor 2 agonist, significantly enhances cognitive function in adults with narcolepsy type 1. This finding emerged from a secondary analysis of a phase 2 clinical trial, which assessed the impact of oveporexton on attention, memory, and executive function over an 8-week period. The study's results were published in JAMA Neurology, offering a promising avenue for managing cognitive symptoms in this patient population.
The analysis, led by Gert Jan Lammers, MD, PhD, and his team, involved 112 participants who were randomly assigned to receive either oveporexton or a placebo. The study's findings demonstrated that oveporexton treatment led to substantial improvements in cognitive measures, including attention, memory, and executive function. Specifically, oveporexton reduced lapses in attention, errors in memory, and slowed performance in executive function tasks, as measured by the Psychomotor Vigilance Task, Continuous Paired Associate Learning test, and One Back and International Digit Symbol Substitution Test, respectively.
Furthermore, the study revealed additional cognitive benefits, such as enhanced working memory, processing speed, and executive function. These improvements were evident across various dose groups, with participants receiving 0.5/0.5 mg, 2/2 mg, 2/5 mg, and 7 mg of oveporexton showing significant gains in cognitive performance compared to the placebo group.
The initial phase 2 trial results, presented at the 2025 SLEEP Annual Meeting, also highlighted oveporexton's ability to reduce microsleep rates and delay the onset of microsleep in patients with narcolepsy type 1. These findings suggest that oveporexton may be a valuable treatment option for managing daytime sleepiness and improving overall wakefulness in adults with narcolepsy type 1.
The study's findings have sparked excitement in the medical community, offering a potential breakthrough in the management of narcolepsy type 1. As further research continues, oveporexton may become a standard treatment, providing adults with narcolepsy type 1 with improved cognitive function and a better quality of life.
